Selective inhibition of the BD2 bromodomain of BET pr

Nature

578, 306-310

DOI: 10.1038/s41586-020-1930-8

Citation Report

#	Article	IF	Citations
1	Ranking Series of Cancer-Related Gene Expression Data by Means of the Superposing Significant Interaction Rules Method. Biomolecules, 2020, 10, 1293.	4.0	1
2	BRD4 Prevents R-Loop Formation and Transcription-Replication Conflicts by Ensuring Efficient Transcription Elongation. Cell Reports, 2020, 32, 108166.	6.4	46
3	A 7-methoxybicoumarin derivative selectively inhibits BRD4 BD2 for anti-melanoma therapy. International Journal of Biological Macromolecules, 2020, 164, 3204-3220.	7.5	24
4	BET bromodomains as novel epigenetic targets for brain health and disease. Neuropharmacology, 2020, 181, 108306.	4.1	30
5	BRD4 (Bromodomain-Containing Protein 4) Interacts with GATA4 (GATA Binding Protein 4) to Govern Mitochondrial Homeostasis in Adult Cardiomyocytes. Circulation, 2020, 142, 2338-2355.	1.6	31
6	Cyclic peptides can engage a single binding pocket through highly divergent modes. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 26728-26738.	7.1	27
7	A guide for bioinformaticians: â€˜omics-based drug discovery for precision oncology. Drug Discovery Today, 2020, 25, 1897-1904.	6.4	10
8	Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children. European Journal of Cancer, 2020, 139, 135-148.	2.8	20
9	Design and Synthesis of a Highly Selective and In Vivo-Capable Inhibitor of the Second Bromodomain of the Bromodomain and Extra Terminal Domain Family of Proteins. Journal of Medicinal Chemistry, 2020, 63, 9070-9092.	6.4	40
10	Super-enhancer in prostate cancer: transcriptional disorders and therapeutic targets. Npj Precision Oncology, 2020, 4, 31.	5.4	19
11	Histone tail analysis reveals H3K36me2 and H4K16ac as epigenetic signatures of diffuse intrinsic pontine glioma. Journal of Experimental and Clinical Cancer Research, 2020, 39, 261.	8.6	16
12	GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins. Journal of Medicinal Chemistry, 2020, 63, 9045-9069.	6.4	59
13	The Optimization of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) Inhibitor. Journal of Medicinal Chemistry, 2020, 63, 9093-9126.	6.4	41
14	Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype. Journal of Medicinal Chemistry, 2020, 63, 9020-9044.	6.4	38
15	Domain-selective targeting of BET proteins in cancer and immunological diseases. Current Opinion in Chemical Biology, 2020, 57, 184-193.	6.1	43
16	Targeting epigenetic reader domains by chemical biology. Current Opinion in Chemical Biology, 2020, 57, 82-94.	6.1	20
17	Stereoselective synthesis of allele-specific BET inhibitors. Organic and Biomolecular Chemistry, 2020, 18, 7533-7539.	2.8	4
18	Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer. Frontiers in Oncology, 2020, 10, 581515.	2.8	27

#	Article	IF	Citations
19	Quantifying the Selectivity of Proteinâ€“Protein and Small Molecule Interactions with Fluorinated Tandem Bromodomain Reader Proteins. ACS Chemical Biology, 2020, 15, 3038-3049.	3.4	4
20	Pharmacological inhibition of syntenin PDZ2 domain impairs breast cancer cell activities and exosome loading with syndecan and EpCAM cargo. Journal of Extracellular Vesicles, 2020, 10, e12039.	12.2	27
22	Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib. Journal of Medicinal Chemistry, 2020, 63, 7186-7210.	6.4	19
23	Targeting epigenetic proteinâ€“protein interactions with small-molecule inhibitors. Future Medicinal Chemistry, 2020, 12, 1305-1326.	2.3	12
24	Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. Science, 2020, 368, 387-394.	12.6	274
25	Selective Targeting of Different Bromodomains by Small Molecules. Cancer Cell, 2020, 37, 764-766.	16.8	5
26	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature, 2020, 583, 459-468.	27.8	3,542
27	GSK973 Is an Inhibitor of the Second Bromodomains (BD2s) of the Bromodomain and Extra-Terminal (BET) Family. ACS Medicinal Chemistry Letters, 2020, 11, 1581-1587.	2.8	25
28	Epigenetic Therapeutics for Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2020, 323, 1557.	7.4	3
29	BET Epigenetic Reader Proteins in Cardiovascular Transcriptional Programs. Circulation Research, 2020, 126, 1190-1208.	4.5	88
30	Discovery of N-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]p (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain. Journal of Medicinal Chemistry, 2020, 63, 5585-5623.	6.4	86
31	Next-generation epigenetic inhibitors. Science, 2020, 368, 367-368.	12.6	20
32	Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy. Acta Pharmaceutica Sinica B, 2021, 11, 156-180.	12.0	49
33	BRD4 regulates key transcription factors that drive epithelialâ€“mesenchymal transition in castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 268-277.	3.9	24
34	Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes. European Journal of Medicinal Chemistry, 2021, 209, 112868.	5.5	32
35	Selective Nâ€Terminal BET Bromodomain Inhibitors by Targeting Nonâ€Conserved Residues and Structured Water Displacement**. Angewandte Chemie, 2021, 133, 1240-1246.	2.0	0
36	BRD9 Is a Critical Regulator of Androgen Receptor Signaling and Prostate Cancer Progression. Cancer Research, 2021, 81, 820-833.	0.9	43
37	Drug design targeting active posttranslational modification protein isoforms. Medicinal Research Reviews, 2021, 41, 1701-1750.	10.5	33

#	Article	IF	Citations
38	COVID-19 outbreak: history, mechanism, transmission, structural studies and therapeutics. Infection, 2021, 49, 199-213.	4.7	160
39	Selective Nâ€Terminal BET Bromodomain Inhibitors by Targeting Nonâ€Conserved Residues and Structured Water Displacement**. Angewandte Chemie - International Edition, 2021, 60, 1220-1226.	13.8	27
40	Inhibitors of bromodomain and extraâ€terminal proteins for treating multiple human diseases. Medicinal Research Reviews, 2021, 41, 223-245.	10.5	74
42	Bromodomain and extraterminal (BET) protein inhibition of IgG/IgE production in murine B cells is counterâ€balanced by a strong Th2 bias. Clinical and Translational Immunology, 2021, 10, e1280.	3.8	1
44	Epigenetics in prostate cancer treatment. , 2021, 5, 341-356.		3
45	Discovery of a Positron Emission Tomography Radiotracer Selectively Targeting the BD1 Bromodomains of BET Proteins. ACS Medicinal Chemistry Letters, 2021, 12, 282-287.	2.8	7
46	Discovery of the natural product 3',4',7,8-tetrahydroxyflavone as a novel and potent selective BRD4 bromodomain 2 inhibitor. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 903-913.	5.2	11
47	Discovery and characterization of bromodomain 2â€“specific inhibitors of BRDT. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	42
48	USP16 regulates castration-resistant prostate cancer cell proliferation by deubiquitinating and stablizing c-Myc. Journal of Experimental and Clinical Cancer Research, 2021, 40, 59.	8.6	31
50	Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy. Journal of Medicinal Chemistry, 2021, 64, 2576-2607.	6.4	91
52	Synthesis, evaluation and in silico studies of novel BRD4 bromodomain inhibitors bearing a benzo[d]isoxazol scaffold. Journal of Chemical Sciences, 2021, 133, 1.	1.5	0
53	Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development. Journal of Medicinal Chemistry, 2021, 64, 2419-2435.	6.4	74
54	Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties. Journal of Medicinal Chemistry, 2021, 64, 2534-2575.	6.4	79
55	Achieving clinical success with BET inhibitors as anti-cancer agents. British Journal of Cancer, 2021, 124, 1478-1490.	6.4	204
56	Co-Operativity between MYC and BCL-2 Pro-Survival Proteins in Cancer. International Journal of Molecular Sciences, 2021, 22, 2841.	4.1	17
57	Bromodomain protein BRDT directs Î”Np63 function and super-enhancer activity in a subset of esophageal squamous cell carcinomas. Cell Death and Differentiation, 2021, 28, 2207-2220.	11.2	18
58	Bromodomain and extra-terminalÂinhibitorsâ€”A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in childrenâ€”ACCELERATE. European Journal of Cancer, 2021, 146, 115-124.	2.8	10
59	ATAD2 interacts with C/EBPÎ² to promote esophageal squamous cell carcinoma metastasis via TGF-Î²1/Smad3 signaling. Journal of Experimental and Clinical Cancer Research, 2021, 40, 109.	8.6	19

#	Article	IF	Citations
60	Androgen receptor enhancer amplification in matched patientâ€derived xenografts of primary and castrateâ€resistant prostate cancer. Journal of Pathology, 2021, 254, 121-134.	4.5	12
61	Template-Hopping Approach Leads to Potent, Selective, and Highly Soluble Bromo and Extraterminal Domain (BET) Second Bromodomain (BD2) Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 3249-3281.	6.4	19
62	BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection. Cell, 2021, 184, 2167-2182.e22.	28.9	131
63	Fast-acting chemical tools to delineate causality in transcriptional control. Molecular Cell, 2021, 81, 1617-1630.	9.7	44
64	The BET inhibitor attenuates the inflammatory response and cell migration in human microglial HMC3Âcell line. Scientific Reports, 2021, 11, 8828.	3.3	29
65	Selective Targeting of Epigenetic Readers and Histone Deacetylases in Autoimmune and Inflammatory Diseases: Recent Advances and Future Perspectives. Journal of Personalized Medicine, 2021, 11, 336.	2.5	13
66	Advances in targeting â€˜undruggableâ€™ transcription factors with small molecules. Nature Reviews Drug Discovery, 2021, 20, 669-688.	46.4	152
67	Brief review on repurposed drugs and vaccines for possible treatment of COVID-19. European Journal of Pharmacology, 2021, 898, 173977.	3.5	29
68	Design, synthesis, biological evaluation, and molecular docking of 1,7-dibenzyl-substituted theophylline derivatives as novel BRD4-BD1-selective inhibitors. Medicinal Chemistry Research, 2021, 30, 1453-1468.	2.4	1
69	Enhancer rewiring in tumors: an opportunity for therapeutic intervention. Oncogene, 2021, 40, 3475-3491.	5.9	10
70	Synthesis and Characterization of a Positron Emission Tomography Imaging Probe Selectively Targeting the Second Bromodomain of Bromodomain Protein BRD4. Bioconjugate Chemistry, 2021, 32, 1711-1718.	3.6	7
71	BET inhibitor suppresses migration of human hepatocellular carcinoma by inhibiting SMARCA4. Scientific Reports, 2021, 11, 11799.	3.3	17
72	<scp>T</scp>herapeutic targeting of chromatin: status and opportunities. FEBS Journal, 2022, 289, 1276-1301.	4.7	10
73	BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program. Clinical Cancer Research, 2021, 27, 4923-4936.	7.0	33
75	Discovery of a Highly Selective BET BD2 Inhibitor from a DNA-Encoded Library Technology Screening Hit. Journal of Medicinal Chemistry, 2021, 64, 10806-10833.	6.4	31
76	Recent Advances in Epigenetic Biomarkers and Epigenetic Targeting in Prostate Cancer. European Urology, 2021, 80, 71-81.	1.9	35
77	Optimization of a Series of 2,3-Dihydrobenzofurans as Highly Potent, Second Bromodomain (BD2)-Selective, Bromo and Extra-Terminal Domain (BET) Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 10711-10741.	6.4	17
78	Identification of a Series of N-Methylpyridine-2-carboxamides as Potent and Selective Inhibitors of the Second Bromodomain (BD2) of the Bromo and Extra Terminal Domain (BET) Proteins. Journal of Medicinal Chemistry, 2021, 64, 10742-10771.	6.4	14

#	Article	IF	Citations
79	Fragment-based Scaffold Hopping: Identification of Potent, Selective, and Highly Soluble Bromo and Extra Terminal Domain (BET) Second Bromodomain (BD2) Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 10772-10805.	6.4	17
80	Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia. Molecular Cancer Therapeutics, 2021, 20, 1809-1819.	4.1	17
81	Functional Roles of Bromodomain Proteins in Cancer. Cancers, 2021, 13, 3606.	3.7	28
82	Chromatin and Epigenetic Dysregulation of Prostate Cancer Development, Progression, and Therapeutic Response. Cancers, 2021, 13, 3325.	3.7	14
83	4-Methyl-1,2,3-Triazoles as N-Acetyl-Lysine Mimics Afford Potent BET Bromodomain Inhibitors with Improved Selectivity. Journal of Medicinal Chemistry, 2021, 64, 10497-10511.	6.4	22
84	Next generation epigenetic modulators to target myeloid neoplasms. Current Opinion in Hematology, 2021, 28, 356-363.	2.5	1
85	Mutational Landscape and Interaction of SARS-CoV-2 with Host Cellular Components. Microorganisms, 2021, 9, 1794.	3.6	9
86	Improved methods for targeting epigenetic reader domains of acetylated and methylated lysine. Current Opinion in Chemical Biology, 2021, 63, 132-144.	6.1	14
87	Post-translational lysine ac(et)ylation in health, ageing and disease. Biological Chemistry, 2022, 403, 151-194.	2.5	15
88	Discovery of High-Affinity Inhibitors of the BPTF Bromodomain. Journal of Medicinal Chemistry, 2021, 64, 12075-12088.	6.4	15
89	Enhancers in disease: molecular basis and emerging treatment strategies. Trends in Molecular Medicine, 2021, 27, 1060-1073.	6.7	84
90	Structural investigation of tetrahydropteridin analogues as selective PLK1 inhibitors for treating cancer through combined QSAR techniques, molecular docking, and molecular dynamics simulations. Journal of Molecular Liquids, 2021, 335, 116235.	4.9	17
91	Binding specificity and function of the SWI/SNF subunit SMARCA4 bromodomain interaction with acetylated histone H3K14. Journal of Biological Chemistry, 2021, 297, 101145.	3.4	3
92	From Hit Seeking to Magic Bullets: The Successful Union of Epigenetic and Fragment Based Drug Discovery (EPIDD + FBDD). Journal of Medicinal Chemistry, 2021, 64, 13980-14010.	6.4	12
93	The Functions of BET Proteins in Gene Transcription of Biology and Diseases. Frontiers in Molecular Biosciences, 2021, 8, 728777.	3.5	56
94	Development of Murine Leukemia Virus Integrase-Derived Peptides That Bind Brd4 Extra-Terminal Domain as Candidates for Suppression of Acute Myeloid Leukemia. ACS Pharmacology and Translational Science, 2021, 4, 1628-1638.	4.9	9
95	Selectively targeting individual bromodomain: Drug discovery and molecular mechanisms. Pharmacological Research, 2021, 172, 105804.	7.1	16
96	Structure-guided discovery of novel potent and efficacious proteolysis targeting chimera (PROTAC) degrader of BRD4. Bioorganic Chemistry, 2021, 115, 105238.	4.1	13

#	Article	IF	Citations
97	Research progress of dual inhibitors targeting crosstalk between histone epigenetic modulators for cancer therapy. European Journal of Medicinal Chemistry, 2021, 222, 113588.	5.5	20
98	Bromodomains: A novel target for the anticancer therapy. European Journal of Pharmacology, 2021, 911, 174523.	3.5	17
99	Fragment-based drug design targeting syntenin PDZ2 domain involved in exosomal release and tumour spread. European Journal of Medicinal Chemistry, 2021, 223, 113601.	5.5	3
100	Progress in the development of domain selective inhibitors of the bromo and extra terminal domain family (BET) proteins. European Journal of Medicinal Chemistry, 2021, 226, 113853.	5.5	9
101	Supercharging BRD4 with NUT in carcinoma. Oncogene, 2021, 40, 1396-1408.	5.9	48
107	Pharmacotherapy for SARS-CoV-2 and Seizures for Drug Repurposing Presumed on Mechanistic Targets. Current Molecular Pharmacology, 2022, 15, 832-845.	1.5	1
108	Dualâ€target inhibitors of bromodomain and extraâ€terminal proteins in cancer: A review from medicinal chemistry perspectives. Medicinal Research Reviews, 2022, 42, 710-743.	10.5	27
109	BRD4 in physiology and pathology: â€˜â€˜BETâ€™â€™ on its partners. BioEssays, 2021, 43, e2100180.	2.5	28
110	Inhibition of Bromodomain and Extra Terminal (BET) Domain Activity Modulates the IL-23R/IL-17 Axis and Suppresses Acute Graft-Versus-Host Disease. Frontiers in Oncology, 2021, 11, 760789.	2.8	7
111	Development of a Novel Positron Emission Tomography (PET) Radiotracer Targeting Bromodomain and Extra-Terminal Domain (BET) Family Proteins. Frontiers in Molecular Biosciences, 2020, 7, 198.	3.5	4
113	Differential BET Bromodomain Inhibition by Dihydropteridinone and Pyrimidodiazepinone Kinase Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 15772-15786.	6.4	10
114	Discovery of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy. European Journal of Medicinal Chemistry, 2022, 227, 113953.	5.5	12
115	Widening the window of bromodomain inhibition. Nature Reviews Drug Discovery, 2020, 19, 166-166.	46.4	0
116	Pharmacological Regulation and Functional Significance of Chromatin Binding by BET Tandem Bromodomains. RSC Drug Discovery Series, 2020, , 209-248.	0.3	0
117	Improving TRAIL-induced apoptosis in cancers by interfering with histone modifications. , 2020, 3, 791-803.		0
118	Medicinal Chemistry. , 2020, , 143-163.		0
120	BRD4 drives esophageal squamous cell carcinoma growth by promoting RCC2 expression. Oncogene, 2022, 41, 347-360.	5.9	15
121	Phosphorylation-dependent BRD4 dimerization and implications for therapeutic inhibition of BET family proteins. Communications Biology, 2021, 4, 1273.	4.4	10

#	Article	IF	Citations
122	BETting on next-generation bromodomain inhibitors. American Journal of Clinical and Experimental Urology, 2020, 8, 129-132.	0.4	0
124	Design, Synthesis, and Characterization of I-BET567, a Pan-Bromodomain and Extra Terminal (BET) Bromodomain Oral Candidate. Journal of Medicinal Chemistry, 2022, 65, 2262-2287.	6.4	14
125	Chromatin Remodeling Induced by ARID1A Loss in Lung Cancer Promotes Glycolysis and Confers JQ1 Vulnerability. Cancer Research, 2022, 82, 791-804.	0.9	22
126	Design, synthesis, and evaluation of novel pyridone derivatives as potent BRD4 inhibitors for the potential treatment of prostate cancer. Bioorganic Chemistry, 2022, 119, 105575.	4.1	6
127	BRD2 inhibition blocks SARS-CoV-2 infection by reducing transcription of the host cell receptor ACE2. Nature Cell Biology, 2022, 24, 24-34.	10.3	47
128	A Structure-based Design Approach for Generating High Affinity BRD4 D1-Selective Chemical Probes. Journal of Medicinal Chemistry, 2022, 65, 2342-2360.	6.4	19
129	Discovery, X-ray Crystallography, and Anti-inflammatory Activity of Bromodomain-containing Protein 4 (BRD4) BD1 Inhibitors Targeting a Distinct New Binding Site. Journal of Medicinal Chemistry, 2022, 65, 2388-2408.	6.4	24
130	Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers. World Journal of Gastrointestinal Oncology, 2022, 14, 75-89.	2.0	10
131	Targeting BET Bromodomains in Cancer. Annual Review of Cancer Biology, 2022, 6, 313-336.	4.5	11
132	The binding mechanism of NHWD-870 to bromodomain-containing protein 4 based on molecular dynamics simulations and free energy calculation. Physical Chemistry Chemical Physics, 2022, 24, 5125-5137.	2.8	4
133	Super enhancers as master gene regulators in the pathogenesis of hematologic malignancies. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188697.	7.4	8
134	Recent Developments in Targeting Bromodomain and Extra Terminal Domain Proteins for Cancer Therapeutics. Current Medicinal Chemistry, 2022, 29, 4391-4409.	2.4	3
135	Privileged Scaffolds Targeting Bromodomain-containing Protein 4. Current Topics in Medicinal Chemistry, 2022, 22, .	2.1	2
136	Fragment-to-Lead Medicinal Chemistry Publications in 2020. Journal of Medicinal Chemistry, 2022, 65, 84-99.	6.4	52
137	Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer. Nature, 2022, 601, 434-439.	27.8	110
139	H2B.V demarcates divergent strand-switch regions, some tDNA loci, and genome compartments in Trypanosoma cruzi and affects parasite differentiation and host cell invasion. PLoS Pathogens, 2022, 18, e1009694.	4.7	15
140	New Druggable Targets for Rheumatoid Arthritis Based on Insights From Synovial Biology. Frontiers in Immunology, 2022, 13, 834247.	4.8	11
141	Dicer promotes genome stability via the bromodomain transcriptional co-activator BRD4. Nature Communications, 2022, 13, 1001.	12.8	10

#	Article	IF	Citations
142	CRCM5484: A BET-BDII Selective Compound with Differential Anti-leukemic Drug Modulation. Journal of Medicinal Chemistry, 2022, 65, 5660-5674.	6.4	2
143	Epigenetic regulation of EIF4A1 through DNA methylation and an oncogenic role of eIF4A1 through BRD2 signaling in prostate cancer. Oncogene, 2022, 41, 2778-2785.	5.9	6
144	Design, synthesis and pharmacological characterization of N-(3-ethylbenzo[d]isoxazol-5-yl) sulfonamide derivatives as BRD4 inhibitors against acute myeloid leukemia. Acta Pharmacologica Sinica, 2022, , .	6.1	1
145	Targeting Bromodomain-Selective Inhibitors of BET Proteins in Drug Discovery and Development. Journal of Medicinal Chemistry, 2022, 65, 5184-5211.	6.4	21
146	Structure-Based Discovery and Optimization of Furo[3,2-c]pyridin-4(5H)-one Derivatives as Potent and Second Bromodomain (BD2)-Selective Bromo and Extra Terminal Domain (BET) Inhibitors. Journal of Medicinal Chemistry, 2022, 65, 5760-5799.	6.4	10
147	Quinazoline Based HDAC Dual Inhibitors as Potential Anti-Cancer Agents. Molecules, 2022, 27, 2294.	3.8	17
148	Adjusted degradation of BRD4 S and BRD4 L based on fine structural modifications of the pyrrolopyridone scaffold. European Journal of Medicinal Chemistry, 2022, 236, 114259.	5.5	8
149	Domain-selective BET inhibition attenuates transcriptional and behavioral responses to cocaine. Neuropharmacology, 2022, 210, 109040.	4.1	5
150	Dihydropyridine Lactam Analogs Targeting BET Bromodomains. ChemMedChem, 2022, 17, e202100407.	3.2	1
152	Report of the First International Symposium on NUT Carcinoma. Clinical Cancer Research, 2022, 28, 2493-2505.	7.0	23
153	Novel forms of prostate cancer chemoresistance to successful androgen deprivation therapy demand new approaches: Rationale for targeting BET proteins. Prostate, 2022, 82, 1005-1015.	2.3	8
154	Combined noncanonical NF-Î²B agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo. Journal of Clinical Investigation, 2022, 132, .	8.2	17
155	BET bromodomain inhibitors. Current Opinion in Chemical Biology, 2022, 68, 102148.	6.1	40
158	Combined inhibition of BET bromodomain and mTORC1/2 provides therapeutic advantage for rhabdomyosarcoma by switching cell death mechanism. Molecular Carcinogenesis, 2022, 61, 737-751.	2.7	6
159	Comprehensive transcriptome profiling of BET inhibitor-treated HepG2 cells. PLoS ONE, 2022, 17, e0266966.	2.5	3
160	Dual HDAC/BRD4 Inhibitors Relieves Neuropathic Pain by Attenuating Inflammatory Response in Microglia After Spared Nerve Injury. Neurotherapeutics, 2022, 19, 1634-1648.	4.4	9
161	Discovery of 2-((2-methylbenzyl)thio)-6-oxo-4-(3,4,5-trimethoxyphenyl)-1,6-dihydropyrimidine-5-carbonitrile as a novel and effective bromodomain and extra-terminal (BET) inhibitor for the treatment of sepsis. European Journal of Medicinal Chemistry, 2022, 238, 114423.	5.5	6
162	From Therapy Resistance to Targeted Therapies in Prostate Cancer. Frontiers in Oncology, 2022, 12, .	2.8	10

#	Article	IF	Citations
163	Discovery of potent BET bromodomain 1 stereoselective inhibitors using DNA-encoded chemical library selections. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	15
164	Bromodomain and Extra-Terminal Protein Inhibitors: Biologic Insights and Therapeutic Potential in Pediatric Brain Tumors. Pharmaceuticals, 2022, 15, 665.	3.8	5
165	BRD4 promotes resection and homology-directed repair of DNA double-strand breaks. Nature Communications, 2022, 13, .	12.8	17
166	Discovery of <scp>CECR2</scp> Bromodomain Inhibitors with High Selectivities over <scp>BPTF</scp> Bromodomain. Chinese Journal of Chemistry, 2022, 40, 2072-2080.	4.9	0
167	A direct high-throughput protein quantification strategy facilitates discovery and characterization of a celastrol-derived BRD4 degrader. Cell Chemical Biology, 2022, 29, 1333-1340.e5.	5.2	16
168	Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML. In Vivo, 2022, 36, 1615-1627.	1.3	3
169	Tiny Titans: Nanobodies as Powerful Tools for TRâ€FRET Assay Development. Analysis & Sensing, 2022, 2, .	2.0	2
170	Multifaceted regulation of enhancers in cancer. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2022, 1865, 194839.	1.9	2
171	Identification of Highly Efficacious PROTACs Targeting BRD4 Against Acute Myeloid Leukemia: Design, Synthesis, and Biological Evaluations. SSRN Electronic Journal, 0, , .	0.4	0
172	The Functional Role and Regulatory Mechanism of Bromodomain-Containing Protein 9 in Human Uterine Leiomyosarcoma. Cells, 2022, 11, 2160.	4.1	7
173	Targeting ESR1 mutationâ€“induced transcriptional addiction in breast cancer with BET inhibition. JCI Insight, 2022, 7, .	5.0	4
174	Bivalent BET Bromodomain Inhibitors Confer Increased Potency and Selectivity for BRDT via Protein Conformational Plasticity. Journal of Medicinal Chemistry, 2022, 65, 10441-10458.	6.4	8
175	Discovery of BET specific bromodomain inhibitors with a novel scaffold. Bioorganic and Medicinal Chemistry, 2022, 72, 116967.	3.0	1
176	1,4â€Dihydropyridinebutyrolactoneâ€derived ringâ€opened ester and amide analogs targeting BET bromodomains. Archiv Der Pharmazie, 2022, 355, .	4.1	1
177	Resistance to prostate cancer treatments. IUBMB Life, 2023, 75, 390-410.	3.4	4
178	BET inhibitors: an updated patent review (2018â€“2021). Expert Opinion on Therapeutic Patents, 2022, 32, 953-968.	5.0	7
179	BET inhibition triggers antitumor immunity by enhancing MHC class I expression in head and neck squamous cell carcinoma. Molecular Therapy, 2022, 30, 3394-3413.	8.2	6
180	N-terminal BET bromodomain inhibitors disrupt a BRD4-p65 interaction and reduce inducible nitric oxide synthase transcription in pancreatic Î²-cells. Frontiers in Endocrinology, 0, 13, .	3.5	2

#	Article	IF	Citations
181	A positron emission tomography imaging probe selectively targeting the BD1 bromodomain and extra-terminal domain. Chemical Communications, 2022, 58, 9654-9657.	4.1	1
182	Prostate Cancer Epigenetic Plasticity and Enhancer Heterogeneity: Molecular Causes, Consequences and Clinical Implications. Advances in Experimental Medicine and Biology, 2022, , 255-275.	1.6	1
183	Decoding mechanism of action and sensitivity to drug candidates from integrated transcriptome and chromatin state. ELife, 0, 11, .	6.0	3
184	Roles of Bromodomain Extra Terminal Proteins in Metabolic Signaling and Diseases. Pharmaceuticals, 2022, 15, 1032.	3.8	1
185	Development of an N-Terminal BRD4 Bromodomain-Targeted Degrader. ACS Medicinal Chemistry Letters, 2022, 13, 1621-1627.	2.8	4
186	Targeting bromodomain and extra-terminal proteins to inhibit neuroblastoma tumorigenesis through regulating MYCN. Frontiers in Cell and Developmental Biology, 0, 10, .	3.7	2
187	Cellular specificity of androgen receptor, coregulators, and pioneer factors in prostate cancer. Endocrine Oncology, 2022, 2, R112-R131.	0.4	4
188	The role of protein acetylation in carcinogenesis and targeted drug discovery. Frontiers in Endocrinology, 0, 13, .	3.5	9
189	Targeting the Heterogeneous Genomic Landscape in Triple-Negative Breast Cancer through Inhibitors of the Transcriptional Machinery. Cancers, 2022, 14, 4353.	3.7	3
190	A comprehensive review of BET-targeting PROTACs for cancer therapy. Bioorganic and Medicinal Chemistry, 2022, 73, 117033.	3.0	9
191	Transcriptional plasticity of fibroblasts in heart disease. Biochemical Society Transactions, 2022, 50, 1247-1255.	3.4	1
192	Cyclization strategy leads to highly potent Bromodomain and extra-terminal (BET) Bromodomain inhibitors for the treatment of acute liver injury. European Journal of Medicinal Chemistry, 2023, 247, 115023.	5.5	2
193	BRD8 maintains glioblastoma by epigenetic reprogramming of the p53 network. Nature, 2023, 613, 195-202.	27.8	15
194	Immune microenvironment infiltration landscape and immune-related subtypes in prostate cancer. Frontiers in Immunology, 0, 13, .	4.8	4
196	Characterizing crosstalk in epigenetic signaling to understand disease physiology. Biochemical Journal, 2023, 480, 57-85.	3.7	4
197	BRD4â€PRC2 represses transcription of Tâ€helper 2â€specific negative regulators during Tâ€cell differentiation. EMBO Journal, 2023, 42, .	7.8	6
198	Interrogating bromodomain inhibitor resistance in KMT2A-rearranged leukemia through combinatorial CRISPR screens. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	7.1	4
199	Rational design, synthesis and biological evaluation of benzo[d]isoxazole derivatives as potent BET bivalent inhibitors for potential treatment of prostate cancer. Bioorganic Chemistry, 2023, 135, 106495.	4.1	1

#	Article	IF	Citations
200	Design, synthesis and biological evaluation of purine-based derivatives as novel JAK2/BRD4(BD2) dual target inhibitors. Bioorganic Chemistry, 2023, 132, 106386.	4.1	2
201	The Emerging Role of Super-enhancers as Therapeutic Targets in The Digestive System Tumors. International Journal of Biological Sciences, 2023, 19, 1036-1048.	6.4	2
202	BET proteins: Biological functions and therapeutic interventions. , 2023, 243, 108354.		6
203	In Silico Screening of Drugs That Target Different Forms of E Protein for Potential Treatment of COVID-19. Pharmaceuticals, 2023, 16, 296.	3.8	2
204	Targeting epigenetic regulation for cancer therapy using small molecule inhibitors. Advances in Cancer Research, 2023, , 73-161.	5.0	5
205	Selective mechanism of inhibitors to two bromodomains of BRD4 revealed by multiple replica molecular dynamics simulations and free energy analyses. Chinese Journal of Chemical Physics, 2023, 36, 725-739.	1.3	3
206	Role of bromodomain and extraterminal (BET) proteins in prostate cancer. Expert Opinion on Investigational Drugs, 2023, 32, 213-228.	4.1	3
207	Recent progress and structural analyses of domainâ€selective BET inhibitors. Medicinal Research Reviews, 2023, 43, 972-1018.	10.5	9
208	A folic acid-decorated nanoparticles loaded JQ1 for oral squamous cell carcinoma therapy. Chinese Chemical Letters, 2024, 35, 108433.	9.0	1
209	The Epigenetic Reader, Bromodomain Containing 2, MediatesÂCholangiocyte Senescence via Interaction With ETS Proto-Oncogene 1. Gastroenterology, 2023, 165, 228-243.e2.	1.3	2
210	Repurposing clinically available drugs and therapies for pathogenic targets to combat SARSâ€CoVâ€2. MedComm, 2023, 4, .	7.2	1
211	Chemical Inhibition of Bromodomain Proteins in Insect-Stage African Trypanosomes Perturbs Silencing of the Variant Surface Glycoprotein Repertoire and Results in Widespread Changes in the Transcriptome. Microbiology Spectrum, 2023, 11, .	3.0	2
212	BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications. Molecules, 2023, 28, 3043.	3.8	8
213	Therapeutic applications of the prostate cancer epigenome. , 2023, , 301-337.		0
214	Recent advances in the development of peptide-based inhibitors targeting epigenetic readers of histone lysine acetylation and methylation marks. Current Opinion in Chemical Biology, 2023, 75, 102334.	6.1	2
215	Selective BD2 Inhibitor Exerts Anti-Fibrotic Effects via BRD4/FoxM1/Plk1 Axis in Orbital Fibroblasts From Patients With Thyroid Eye Disease. , 2023, 64, 9.		0
216	Precise Conformational Control Yielding Highly Potent and Exceptionally Selective BRD4 Degraders with Strong Antitumor Activity. Journal of Medicinal Chemistry, 2023, 66, 8222-8237.	6.4	1
217	Discovery of 1H-Imidazo[4,5-b]pyridine Derivatives as Potent and Selective BET Inhibitors for the Management of Neuropathic Pain. Journal of Medicinal Chemistry, 2023, 66, 8725-8744.	6.4	3

#	Article	IF	Citations
218	The importance of microvascular inflammation in ageing and age-related diseases: a position paper from the ESH working group on small arteries, section of microvascular inflammation. Journal of Hypertension, 2023, 41, 1521-1543.	0.5	6
219	Targeting bromodomain-containing proteins: research advances of drug discovery. Molecular Biomedicine, 2023, 4, .	4.4	4
220	å°ê^†åè›‹ç™½ä¾'ä½œè°ƒèŠ‚å‰‰çš„ç”©ç©¶è¿›å±•. Chinese Science Bulletin, 2023, , .	0.7	0
222	Crystal structure of [1,2,4]triazolo[4,3-b]pyridazine derivatives as BRD4 bromodomain inhibitors and structureâ€“activity relationship study. Scientific Reports, 2023, 13, .	3.3	1
223	Photoaffinity labelling displacement assay using multiple recombinant protein domains. Biochemical Journal, 0, , .	3.7	0
224	BRD4 Inhibition as a Strategy to Prolong the Response to Standard of Care in Estrogen Receptor-Positive Breast Cancer. Cancers, 2023, 15, 4066.	3.7	2
225	Design and Characterization of 1,3-Dihydro-2H-benzo[d]azepin-2-ones as Rule-of-5 Compliant Bivalent BET Inhibitors. ACS Medicinal Chemistry Letters, 2023, 14, 1231-1236.	2.8	2
227	Recent advances in targeting the â€œundruggableâ€•proteins: from drug discovery to clinical trials. Signal Transduction and Targeted Therapy, 2023, 8, .	17.1	11
228	Selectivity Mechanism of Pyrrolopyridone Analogues Targeting Bromodomain 2 of Bromodomain-Containing Protein 4 from Molecular Dynamics Simulations. ACS Omega, 2023, 8, 33658-33674.	3.5	0
229	Discovery of a Bromodomain and Extra Terminal Domain (BET) Inhibitor with the Selectivity for the Second Bromodomain (BD2) and the Capacity for the Treatment of Inflammatory Diseases. Journal of Medicinal Chemistry, 2023, 66, 10824-10848.	6.4	2
230	Acetyl-methyllysine marks chromatin at active transcription start sites. Nature, 2023, 622, 173-179.	27.8	6
231	Novel Aminopyrimidine-2,4-diones, 2-Thiopyrimidine-4-ones, and 6-Arylpteridines as Dual-Target Inhibitors of BRD4/PLK1: Design, Synthesis, Cytotoxicity, and Computational Studies. Pharmaceuticals, 2023, 16, 1303.	3.8	1
232	GNE-235: A Lead Compound Selective for the Second Bromodomain of PBRM1. Journal of Medicinal Chemistry, 2023, 66, 13116-13134.	6.4	1
233	Targeting the epigenetic reader â€œBETâ€•as a therapeutic strategy for cancer. Bioorganic Chemistry, 2023, 140, 106833.	4.1	1
234	EZH2 Cooperates with BRD4-NUT to Drive NUT Carcinoma Growth by Silencing Key Tumor Suppressor Genes. Cancer Research, 2023, 83, 3956-3973.	0.9	1
235	ABBV-744 induces autophagy in gastric cancer cells by regulating PI3K/AKT/mTOR/p70S6k and MAPK signaling pathways. Neoplasia, 2023, 45, 100936.	5.3	1
236	The bromodomain acyl-lysine readers in human health and disease. , 2024, , 57-97.		0
238	The BRD4â€“NUT Fusion Alone Drives Malignant Transformation of NUT Carcinoma. Cancer Research, 2023, 83, 3846-3860.	0.9	2

#	Article	IF	Citations
239	Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy. Signal Transduction and Targeted Therapy, 2023, 8, .	17.1	7
240	New Flavone Derivatives Targeting BET Proteins in Cancer: Synthesis, Structure Analysis and Investigation of Bromodomain Inhibitory Activities**. ChemistrySelect, 2023, 8, .	1.5	0
241	Targeting Histone Deacetylases 6 in Dual-Target Therapy of Cancer. Pharmaceutics, 2023, 15, 2581.	4.5	0
242	Domain-Selective BET Ligands Yield Next-Generation Synthetic Genome Readers/Regulators with Nonidentical Cellular Functions. Journal of the American Chemical Society, 0, , .	13.7	1
243	Structure-Guided Design of a Domain-Selective Bromodomain and Extra Terminal N-Terminal Bromodomain Chemical Probe. Journal of Medicinal Chemistry, 0, , .	6.4	0
244	DW71177: A novel [1,2,4]triazolo[4,3-a]quinoxaline-based potent and BD1-Selective BET inhibitor for the treatment of acute myeloid leukemia. European Journal of Medicinal Chemistry, 2024, 265, 116052.	5.5	0
245	Epigenetic (De)regulation in Prostate Cancer. Cancer Treatment and Research, 2023, , 321-360.	0.5	0
246	Discovery of a brain-permeable bromodomain and extra terminal domain (BET) inhibitor with selectivity for BD1 for the treatment of multiple sclerosis. European Journal of Medicinal Chemistry, 2024, 265, 116080.	5.5	1
247	Super-enhancers and the super-enhancer reader BRD4: tumorigenic factors and therapeutic targets. Cell Death Discovery, 2023, 9, .	4.7	1
248	Noval advance of histone modification in inflammatory skin diseases and related treatment methods. Frontiers in Immunology, 0, 14, .	4.8	0
249	Cancer epigenetics: from laboratory studies and clinical trials to precision medicine. Cell Death Discovery, 2024, 10, .	4.7	0
250	Optimization of the synthesis of BET BD2 selective inhibitor XY153. Chemistry and Biodiversity, 2024, 21, .	2.1	0
251	Screening Ultra-Large Encoded Compound Libraries Leads to Novel Proteinâ€“Ligand Interactions and High Selectivity. Journal of Medicinal Chemistry, 2024, 67, 864-884.	6.4	0
252	Discovery of Novel Phenoxyaryl Pyridones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with High Selectivity for the Second Bromodomain (BD2) to Potentially Treat Acute Myeloid Leukemia. Journal of Medicinal Chemistry, 2024, 67, 1513-1532.	6.4	0
253	Structure-Guided Design and Synthesis of Pyridinone-Based Selective Bromodomain and Extra-Terminal Domain (BET)-First Bromodomain (BD1) Inhibitors. Journal of Medicinal Chemistry, 2024, 67, 2712-2731.	6.4	0
254	Epigenetic regulation in cancer. MedComm, 2024, 5, .	7.2	0
255	The C-terminal protein interaction domain of the chromatin reader Yaf9 is critical for pathogenesis of Candida albicans. MSphere, 2024, 9, .	2.9	0
256	Targeting bromodomian-containing protein 8 (BRD8): An advanced tool to interrogate BRD8. European Journal of Medicinal Chemistry, 2024, 268, 116271.	5.5	0

#	Article	IF	Citations
258	Super-Enhancers and Their Parts: From Prediction Efforts to Pathognomonic Status. International Journal of Molecular Sciences, 2024, 25, 3103.	4.1	0